Hologic, Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 538 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $39.40, for a total transaction of $21,197.20. Following the transaction, the vice president now owns 8,343 shares in the company, valued at approximately $328,714.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Hologic, Inc. (NASDAQ HOLX) traded up $0.44 during trading hours on Tuesday, hitting $39.50. 2,796,928 shares of the stock traded hands, compared to its average volume of 3,020,000. Hologic, Inc. has a 12 month low of $35.76 and a 12 month high of $46.80. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.65 and a current ratio of 0.85. The firm has a market cap of $11,010.00, a PE ratio of 19.39, a price-to-earnings-growth ratio of 1.74 and a beta of 0.93.

TRADEMARK VIOLATION WARNING: “Karleen Marie Oberton Sells 538 Shares of Hologic, Inc. (HOLX) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/07/karleen-marie-oberton-sells-538-shares-of-hologic-inc-holx-stock.html.

HOLX has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Monday, October 2nd. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Deutsche Bank AG reduced their price target on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Royal Bank Of Canada reduced their price target on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday, August 3rd. Finally, Barclays PLC reduced their price target on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $47.77.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its holdings in Hologic by 107.6% during the third quarter. SG Americas Securities LLC now owns 34,916 shares of the medical equipment provider’s stock valued at $1,281,000 after purchasing an additional 18,096 shares during the period. RKL Wealth Management LLC lifted its stake in Hologic by 21.6% in the third quarter. RKL Wealth Management LLC now owns 23,885 shares of the medical equipment provider’s stock valued at $875,000 after buying an additional 4,250 shares in the last quarter. Thompson Investment Management Inc. lifted its position in shares of Hologic by 3.6% in the third quarter. Thompson Investment Management Inc. now owns 78,923 shares of the medical equipment provider’s stock worth $2,896,000 after purchasing an additional 2,764 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Hologic by 9.3% in the third quarter. Advisors Asset Management Inc. now owns 18,140 shares of the medical equipment provider’s stock worth $666,000 after purchasing an additional 1,538 shares in the last quarter. Finally, Quantbot Technologies LP lifted its position in shares of Hologic by 3,975.5% in the third quarter. Quantbot Technologies LP now owns 288,140 shares of the medical equipment provider’s stock worth $10,571,000 after purchasing an additional 281,070 shares in the last quarter. Hedge funds and other institutional investors own 96.04% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.